Which first-line biologic’s QoL stands the test of time?

Dear {{accTitle}} {{accLname}},

If you would like to discuss this new data, or anything else, please feel free to contact me.

 

Best regards,

{{userName}}

{{User.Title}}

{{userEmailAddress}}

{{User.MobilePhone}}

CLICK HERE TO VIEW FULL PRODUCT INFORMATION IN ENGLISH

References: 1.Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo-and active comparator-controlled VOYAGE 1 trial. J Am AcadDermatol 2017;76(3):405–417. 2. Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from VOYAGE 1 and VOYAGE 2 trials. J Am AcadDermatol 2020;82:936–45. 3. Griffiths CEM, Papp KA, Song M, et al. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. J DermatologTreat 2020;13:1–9. 4. Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2019;180:1039–49. 5. Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019;394:831-839. 6. Langley RG, Tsai T-F, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018;178(1):114–123.

To report an adverse event, contact our pharmacovigilance department on tel: +27 (0) 11 518 7100 or email: AdverseEventZA@its.jnj.com

Please reply to {{userEmailAddress}} should you wish to opt-out/unsubscribe